News

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase
Gain insights into Exelixis' Q2 2025 performance: 19% cabozantinib revenue growth, NET market leadership, and strategic advancements.